The abstract is read at the publisher; the summary is JClub's.
The National Center Biobank Network (NCBN) has amassed more than 250,000 participants and 800,000 human biospecimens by end of March 2026, spanning multiple disease-focused sample types.
- Why it matters: Japan needs traceable, clinically annotated biospecimens and genomic data to support translational research, biomarker discovery, and genomic medicine.
- What they did: This network of biobanks from five National Centers and JIHS collects blood and DNA, with spinal fluid and frozen tissue added by disease, alongside specialized clinical information and some whole-genome sequencing data.
- The result: These NCBN resources provide a platform for translational research, biomarker discovery, and genomic medicine in Japan, enabled by linked clinical and genomic datasets.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.